For decades, mono
androgen deprivation
therapy (ADT) has been the gold standard for metastatic
hormone-sensitive
prostate cancer (mHSPC) treatment. Several studies have been published within the last seven years demonstrating a significant survival advantage by combination treatment with standard ADT plus
docetaxel or
androgen receptor-axis-targeted
therapy (ARAT) compared to ADT monotherapy. As a result, overall survival can be prolonged by at least 18 months. Recently published congress data of the PEACE-1 study suggests that in the future, triple
therapy might be the new gold standard. In addition to this study, which has shown that triple treatment with standard ADT plus
docetaxel plus
abiraterone is superior to standard ADT plus
docetaxel, several other phase III triple
therapy studies are currently ongoing. The different modes of action that are investigated reach from AR-targeting over mitotic inhibition and
immunotherapy to PARP and AKT inhibition. In this review we will explore if triple
therapy has the potential to be the new standard for mHSPC treatment in the near future.